CA2151409A1 - Formulation pour stabiliser les gammaglobulines humaines - Google Patents
Formulation pour stabiliser les gammaglobulines humainesInfo
- Publication number
- CA2151409A1 CA2151409A1 CA 2151409 CA2151409A CA2151409A1 CA 2151409 A1 CA2151409 A1 CA 2151409A1 CA 2151409 CA2151409 CA 2151409 CA 2151409 A CA2151409 A CA 2151409A CA 2151409 A1 CA2151409 A1 CA 2151409A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- human immunoglobulins
- immunoglobulins
- stabilizing human
- stabilizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 229940072221 immunoglobulins Drugs 0.000 title abstract 3
- 230000000087 stabilizing effect Effects 0.000 title abstract 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000013681 dietary sucrose Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940102223 injectable solution Drugs 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AR33196095 | 1995-05-05 | ||
| AR331,960 | 1995-05-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2151409A1 true CA2151409A1 (fr) | 1996-11-06 |
| CA2151409C CA2151409C (fr) | 2000-08-15 |
Family
ID=3478952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2151409 Expired - Fee Related CA2151409C (fr) | 1995-05-05 | 1995-06-09 | Formulation pour stabiliser les gammaglobulines humaines |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2151409C (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998044948A2 (fr) * | 1997-04-07 | 1998-10-15 | Cangene Corporation | Composition intraveineuse d'immunoglobuline contenant un tensioactif non ionique aux proprietes pharmacocinetiques ameliorees |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
-
1995
- 1995-06-09 CA CA 2151409 patent/CA2151409C/fr not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998044948A2 (fr) * | 1997-04-07 | 1998-10-15 | Cangene Corporation | Composition intraveineuse d'immunoglobuline contenant un tensioactif non ionique aux proprietes pharmacocinetiques ameliorees |
| WO1998044948A3 (fr) * | 1997-04-07 | 1999-02-11 | Cangene Corp | Composition intraveineuse d'immunoglobuline contenant un tensioactif non ionique aux proprietes pharmacocinetiques ameliorees |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2151409C (fr) | 2000-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2292730A1 (fr) | Formulation stabilisee renfermant un anticorps | |
| WO1998022136A3 (fr) | Preparations pharmaceutiques lyophilisees stables d'anticorps monoclonaux ou polyclonaux | |
| CA2156255A1 (fr) | Dispositif a semi-conducteur | |
| CA2234282A1 (fr) | Complexes medicament/resine stabilises par des chelateurs | |
| EP2258402A3 (fr) | Composition sèche | |
| CA2304010A1 (fr) | Methodes et compositions de blanchiment de dents | |
| FI973828A0 (fi) | Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi | |
| CA2194564A1 (fr) | Formulations aqueuses de risperidone | |
| WO1999032097A3 (fr) | Procede pour prevenir et retarder l'apparition de la maladie d'alzheimer, et composition utilisee a cet effet | |
| NO883926D0 (no) | Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat. | |
| WO1999024076A3 (fr) | Agents diagnostiques et therapeutiques derivatises par salicylate | |
| CA2226548A1 (fr) | Preparations de facteurs de croissance des hepatocytes lyophilises | |
| AU5983696A (en) | Fragile x related proteins, compositions and methods of maki ng and using the same | |
| CA2207103A1 (fr) | Methodes d'identification de l'hemochromatose | |
| HUP9903459A3 (en) | Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same | |
| CA2000569A1 (fr) | Adhesif et produit d'etancheite a base de caoutchouc et procede d'application | |
| CA2094806A1 (fr) | Inhibiteurs acat a base d'aminosulfonyluree | |
| CA2238389A1 (fr) | Nouveaux derives geranyl-geranyle, procede pour les preparer et compositions pharmaceutiques les contenant | |
| IE900251L (en) | Mutants of human antithrombin iii | |
| CA2151409A1 (fr) | Formulation pour stabiliser les gammaglobulines humaines | |
| ZA941199B (en) | Physiologically active compound HS-1 and process for the preparation of the same | |
| CA2272880A1 (fr) | Composition et procede permettant de reduire la sensation d'irritation de la peau | |
| EP0381504A3 (fr) | Dérivés de guanidine | |
| CA2238278A1 (fr) | Proteine antigenique provenant de la malassezia | |
| CA2289861A1 (fr) | Procede de preparation d'un antioxydant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |